SCHEMBL18571024

SCHEMBL18571024

CBC1OCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20437367 0.69
SCHEMBL18800433 0.64
Ammonia Solution, Strong SCHEMBL3830975 0.62
SCHEMBL16596098 0.56 LMNA (0.36)
SCHEMBL3078296 0.56
SCHEMBL5538228 0.56
SCHEMBL245730 0.56
SCHEMBL10095236 0.56
SCHEMBL10097228 0.56
SCHEMBL20227657 0.56

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4389145-A2 INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND THEIR USES Ambrx, Inc. (US) 2024-06-26 EP disclosed
EP-3488870-B1 ANTI-CD70 ANTIBODY DRUG CONJUGATES AMBRX INC (US) 2024-03-20 EP disclosed
EP-3225248-B1 MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES AMBRX INC (US) 2023-06-07 EP disclosed
US-20230028168-A1 Modified Relaxin Polypeptides and Their Uses AMBRX, INC. 2023-01-26 US disclosed
WO-2022212899-A1 ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF AMBRX, INC. (US) 2022-10-06 WO disclosed
US-11344626-B2 Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use SUTRO BIOPHARMA, INC. (US) 2022-05-31 US disclosed
WO-2021183832-A1 INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF AMBRX, INC. (US) 2021-09-16 WO disclosed
EP-3170821-B1 COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES AMBRX INC (US) 2021-09-15 EP disclosed
US-20200299403-A1 ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE SUTRO BIOPHARMA, INC. 2020-09-24 US disclosed
US-20200283543-A1 MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE SUTRO BIOPHARMA INC (US) 2020-09-10 US disclosed
EP-3505534-A1 ANTIBODIES COMPRISING SITESPECIFIC NONNATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE Sutro Biopharma, Inc. (US) 2019-07-03 EP disclosed
EP-3336103-A1 ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE Sutro Biopharma, Inc. (US) 2018-06-20 EP disclosed
US-20180036425-A1 ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE SUTRO BIOPHARMA INC (US) 2018-02-08 US disclosed
EP-3225248-A1 MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES Ambrx, Inc. (US) 2017-10-04 EP disclosed
US-9764039-B2 Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use SUTRO BIOPHARMA, INC. (US) 2017-09-19 US disclosed
EP-3170821-A1 COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES Ambrx, Inc. (US) 2017-05-24 EP disclosed
EP-3135690-A1 MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE Sutro Biopharma, Inc. (US) 2017-03-01 EP disclosed